Navigation Links
Gene signal GS-101 data shows safe and effective inhibition of ophthalmic blood vessel growth
Date:9/1/2009

Lausanne, Switzerland Gene Signal, a company focused on developing innovative drugs to manage angiogenesis based conditions, today announced the publication of interim results from a phase II study suggesting that the antisense oligonucleotide GS-101 (eye drops) is safe and effective at inhibiting and regressing corneal neovascularisation (abnormal new blood vessel growth). Neovascularisation in this part of the eye is a major risk factor in corneal graft rejection, the most common transplantation procedure that saves the sight of approximately 46,000 people worldwide each year.

The data were published in the September 2009 issue of Ophthalmology by researchers led by Claus Cursiefen, MD, from the Department of Ophthalmology at the Friedrich-Alexander University Erlangen-Nrnberg, in Erlangen, Germany. Gene Signal is now conducting an international phase III trial with GS-101 for the prevention of pathologic corneal neovascularisation and thereby corneal graft rejection. GS-101 has been granted Orphan Drug status for this indication in Europe.

"Compared to the placebo group in which 100% of patients suffered from progression of corneal neovascularisation, the optimal GS-101 treatment group showed regression in 86% of patients. We are very encouraged by these results as they represent real progress in the development of GS-101 as a new treatment to combat corneal graft rejection," explained Dr. Claus Cursiefen of the Department of Ophthalmology, Friedrich-Alexander University Erlangen-Nrnberg. "We urgently need new options for the thousands of graft recipients, whose current treatment options for threatened rejection such as immunosuppressants are not ideal due to side effects. GS-101 is the first specific angiogenesis inhibitor that has demonstrated activity at the anterior part of the eye, where numerous diseases associated with pathologic angiogenesis endanger vision."

"The publication of these positive phase II results for G
'/>"/>

Contact: Mike Sinclair
msinclair@halsin.com
44-200-845-955
Halsin Partners
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Scientists find clue to mechanisms of gene signaling and regulation
2. Study finds blocking angiogenesis signaling from inside cell may lead to serious health problems
3. Researchers find signal that switches on eye development -- could lead to eye in a dish
4. Cell response to stress signals predicts tumors in women with common pre-breast cancer
5. Rong Li Lab reports protein interactions of MAP kinase signaling pathway
6. DNA variations signal lupus risk
7. Newly defined signaling pathway could mean better biofuel sources
8. Statistics are insufficient for study of proteins signal system
9. Science expands Science Signaling, featuring research related to medical advances, and more
10. Mitochondrial dysfunction and redox signaling in atrial tachyarrhythmia
11. Presence of certain antibodies signals healthier teeth and gums
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... significant anti-tumour activity in patients with advanced BRAF ... has progressed after chemotherapy, according to phase II ... Madrid, Spain. , "Reports of lung cancers ... because these mutations may be associated with increased ... author Dr David Planchard, pulmonary oncologist at the ...
(Date:9/29/2014)... This news release is available in French . ... 29th, 2014 - The number of days an expectant ... (1998) predicts the epigenetic profile of her child, a ... University Institute and McGill University have detected a distinctive ... aftermath of the massive Quebec ice storm. Five months ...
(Date:9/29/2014)... Ill. Scientists have discovered a previously unknown ... grow and, in the case of estrogen-positive breast ... work reveals new targets for breast cancer therapy ... the most aggressive treatment. , The University of ... Oncogene . , Estrogen pre-activates the unfolded-protein ...
Breaking Biology News(10 mins):Promising results shown with targeted approaches in subsets of non-small cell lung cancer 2Promising results shown with targeted approaches in subsets of non-small cell lung cancer 3Scientists discover a new role for estrogen in the pathology of breast cancer 2
... 26, 2012   Reportlinker.com announces that a ... its catalogue: Biometrics Market ... TechNavio,s analysts forecast the ... a CAGR of 42.4 percent over the ...
... University of Massachusetts Amherst resource economist Sylvia Brandt, with colleagues ... upward for childhood asthma and for the first time include ... study released this week in the early online version of ... of asthma due to pollution is much higher than past ...
... The Department of Energy,s Pacific Northwest National Laboratory ... that improves research sample analysis to the marketplace. ... PNNL is receiving a 2012 award for Excellence ... network that encourages federal laboratories to transfer lab-developed ...
Cached Biology News:Biometrics Market in India 2010 - 2014 2Asthma rate and costs from traffic-related air pollution are much higher than once believed 2PNNL recognized for technology transfer 2
(Date:9/30/2014)... 2014 Lyme Research Alliance ... disease research at universities, today announced the awarding of ... identification, treatment and cure for Lyme and other tick-borne ... most applications in its history—over 20 grant proposals—a 100 ... were pleased to receive so many solid applications from ...
(Date:9/30/2014)... 2014 UFP Technologies, a producer ... has recently introduced a custom insulated shipping container ... The new insulated shipper solves the issue of ... UFP Technologies’ BioShell is a universal storage container ... handling and shipping. The insulated shipper keeps frozen ...
(Date:9/29/2014)... (PRWEB) September 30, 2014 Each ... burn injuries require medical attention. In the military, ... serious complications to battlefield medical care. More than ... and Afghanistan. Burn wounds heal slowly, remain inflamed ... be excessive, physically debilitating and functionally damaging. While ...
(Date:9/29/2014)... 29, 2014 Research and Markets  has ... by Product & Services, End-User , Application - Global ... The global oligonucleotide synthesis market is expected ... in 2014, growing at a CAGR of 9.8% from ... categorized on the basis of products and services, applications, ...
Breaking Biology Technology:Lyme Research Alliance Awards Nearly $600,000 in New Grants 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 3Lyme Research Alliance Awards Nearly $600,000 in New Grants 4UFP Technologies Introduces Insulated Shipping Container For Bulk Drug Transportation 2UFP Technologies Introduces Insulated Shipping Container For Bulk Drug Transportation 3Faster Healing with Fewer Scars 2Oligonucleotide Synthesis (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) Market - Global Forecast to 2019 2Oligonucleotide Synthesis (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) Market - Global Forecast to 2019 3
... MA (July 20, 2011)A consortium led by scientists at the ... world,s most detailed genetic map. A genetic map ... sperm or egg where the DNA from the mother and ... reproductive cell. The biological process whereby this reshuffling occurs is ...
... (Nasdaq: SGMO ) today announced that the company ... July 27, 2011, after the market closes. The press release ... ET, which will be open to the public via telephone ... the financial results and discuss other business matters. ...
... July 20, 2011 Regulus Therapeutics Inc ., ... innovative medicines targeting microRNAs, today announced that it has ... GlaxoSmithKline (GSK), triggering a preclinical milestone payment from GSK. ... its microRNA alliance with GSK, which is focused on ...
Cached Biology Technology:Researchers create the world's most advanced genetic map 2Researchers create the world's most advanced genetic map 3Sangamo BioSciences Announces Second Quarter 2011 Conference Call and Webcast 2Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment 2Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment 3Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment 4
Identify and characterize Phosphoinositide (PI(4,5)P2) binding...
... micro test tubes are used to store ... tubes have uniform walls for uniform heat ... O-ring screw caps. The O-rings are made ... operating range from -55 to 150 degrees ...
... Sac-Cel (Second Antibody Coated CELlulose) was ... Diagnostics of Dartford, Kent, one of the ... world. IDS acquired the product range in ... and clinical biochemists developing their own "in ...
Determine relative degree of protein binding to phosphoinositides...
Biology Products: